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Tumour ceils are known to activate monocytes/macrophages and it has been shown that this stimulation
was conferred by tumour-cell membranes. In order to analyse the relevant structures for tumour cell-
specific TNF-induction monocytes from healthy donors were cultured in the presence of plasma
membrane preparations from Jurkat or K562 cells. Both tumour cell lines revealed a monocyte-
stimulating plasma membrane component of about 45 kDa. The TNF-inducing factor exhibited
characteristics of a glycoprotein with the carbohydrate moiety as the structure responsible for
stimulation. CD2, a glycosylated T-cell specific membrane component, was identified as being involved in
monocyte activation in the case of the Jurkat cells whereas the identity of the activating structure on K562
cells is still unknown. From the data presented here indicating the importance of carbohydrate structures
for monocyte activation we conclude that altered glycosylation of cell surface molecules of tumour cells
might be responsible for tumour cell-induced monocyte stimulation.
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INTRODUCTION MATERIALS AND METHODS
Monocytes and macrophages can be activated [1, 2] by a
variety of substances like bacterial and [3-5] viral [6] agents or
tumour cells [7, 8]. They are able to discriminate between
normal and neoplastic cells and selectively destroy the neo-
plastic cells [9-12]. However, the mechanism of this selectivity
is not clear. Earlier work demonstrated that plasma mem-
brane constituents might contribute to the difference between
normal and tumour cells [9], but so far it has not been possible
to attribute specific recognition of tumour cells by monocytes/
macrophages and the subsequent activation of the mono-
nuclear phagocytes to a tumour-specific antigen. Activation of
monocytes is accompanied by production and secretion of
cytokines, like tumour necrosis factor (TNF). Thus, the
tumour cell-induced activated state of monocytes can be
monitored by their secretion of TNF into the culture super-
natant [8, 13]. In this study we present data indicating that
glycosylated tumour-cell membrane structures are responsible
for tumour cell-specific monocyte stimulation and that in the
case of Jurkat cells this carbohydrate structure is associated
with the CD2 molecule.
Cell cultures. Culture methods of tumour cells and the isolation
procedure for human peripheral blood monocytes from bufFy coats of
healthy donors by density gradient centrifugation on Ficoll-Paque
(Pharmacia, Freiburg. Germany) have been described recently [9].
The cell lines used for this study were Jurkat, a lymphoid CD4 + -cell
line [14], and K562, an erythroleukaemia cell line. The cells were
cultured in RPMI 1640 (Gibco, Glasgow, UK) supplemented with
10% heat-inactivated fetal calf serum (FCS) (GIBCO) and 50 /jg/ml
Gentamycin (Gibco).
UV-irradiation, Cells were irradiated in tissue culture plates, with
500 mj using a Stratalinker UV1800 (Stratagene, La Jolla. C A, USA).
T-cell clones. The human T-cell clones used. C3F8 (CD4') and
3025 (CD8 *, CD2 *, CD3 ' . TCRa^, LDCC) [15]. were derived from
U.M6bius(DKFZ. Heidelberg, Germany). TheT-cells(3x 10*') were
restimulated every 10-14 days with irradiated (2000 rad) human
peripheral blood leukocytes (PBL) (6 x 10 )^, irradiated (6000 rad)
Laz-509 cells (3.5 x 10*) [16] in 20 ml RPMI/FCS supplemented with
IL-2 (10 U/ml).
Glutaraldehyde treatment. Cells were washed in phosphate buffered
saline (PBS) and incubated with PBS containing 1% gtutaraldehyde
for 30 min on ice. Subsequently cells were washed with PBS at least 6
times.
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Periodate treatment. Cells or plasma membranes blotted on
nitrocellulose membranes (NC) (Schleicher und Schlill, Dassel,
Germany) were incubated with sodium periodate (10 mM) in a sodium
acetate buffer (50 mM. pH 4.5) for 60 min at room temperature (RT) in
the dark. Subsequently the same volume of PBS with \% glycine was
added and the incubation was carried on for an additional 30 min. At
the end of the treatment cells were washed with PBS at least twice.
Mycoplasma test. Presence of mycoplasma in culture medium was
tested with a mycoplasma-DNA-hybridization kit according to the
manufacturer's instructions (Gen Probe. San Diego. CA, USA).
TNF assay. Mcnocytes (purified by plastic adherence from 5x10*
PBL)were cultured inO.5m! RPMI l640supplemented with 5% FCS
for 18-20 h ina24-wetl tissue culture plate (Costar, Cambridge, MA,
USA). Cell-free supernatants were harvested and the TNF concentra-
tions were measured immediately.
TNF concentrations were detennined by an enzyme-linked immu-
nosorbent assay (ELISA). Unless noted otherwise, all reactions were
carried out at RT. Wells (96-well flat bottom. Titertek Immuno
Assay-Plate, Flow Laboratories, Meckenheim. Germany) were
coated with affinity-purified (Protein A-Diasorb, Diagen. Dusseldorf.
Germany) polyclona! rabbit anti-rhTNF antibodies (Ab) at 5 /ig/ml
in NaHCO:( buffer (50 mM. pH 9) overnight at 4 C . Serial dilutions of
the supernatants in PBS/0.1'l^ i bovine serum albumin (BSA) were
applied to the wells (0.1 ml/well) for 2 h after blocking the wells with
PBS/1% BSA for 2 h. Wells were washed with PBS/0.05% Tween20.
Subsequently mouse anti-rhTNF MoAb I4B3 were added at 1 /ig/ml
in PBS/0.1% BSA to the wells and incubated for 2 h. Wells were
washed and rabbit anti-mouse-IgG peroxidase conjugate (Sigma. St.
Louis MO. USA) at a 1:2000 dilution in PBS was applied for 2 h.
Wells were washed intensively and the substrate solution (3,3'.5.5'-
Tetramethylbenzidine (lOmg) in 100 ml sodium acetate/citric acid
bufTer (100 mM, pH 4,9) and 15 ^i\ ?.(}'%. H.O.) was added (50 pVvjsW),
The reaction was stopped with 2 M HiSOj (50/il/well) and absorption
was measured at 450 nm in an EASY-Reader (SLT-lnstruments).
compared to a standard curve obtained with rhTNF. The MoAb
i4B3 are specific for rhTNF (no cross reaction with h-Lympho-
toxin).
Membrane preparation. Cells (10') were incubated with 10 ml lysis
buffer (Tris/HCL 25 mM, pH 7.4; NaCl 140 mM; PSMF I mM;
Tween40 2.5"/,) for I h at 4 C. Subsequently, the cells were
homogenized with a Potter apparatus and the suspension was
centrifuged for 10 min at 1500 xg to remove the nuclei. The
supernatant was centrifuged again for 1 h at 100,000 xg. This
supernatant was discarded and the pellet was resuspended with I ml
Tris/HCl (10 mM, pH 8) containing 2% sodium deoxycholate (DOC).
This suspension was centrifuged for 1 h at 100,000 x g. This time the
pellet was discarded and the supernatant was either used immediately
or frozen at — TO'^ C^.
Gel-filtration. HPLC gel permeation chromatography was per-
formed using Beckman System Gold equipment with a Beckman TSK
3000SW column. Tris/HCl buffer (150 mM. pH 8) at a fiow rate of 0.5
ml/min was used for elution. Collected fractions were dialysed in
RPMI 1640 (100-fold excess). The proteins used for calibration were
BSA (67 kDa). ovalbumin (43 kDa). and a-chymotrypsinogen (25
kDa).
Gtycosylation inhibitors. Jurkat cells (2x10*') were cultured in
RPMI/FCS culture medium supplemented with swainsonine (10 /iM).
castanospermine (530 /IM). I-deoxymannojirimycin (DMM) (150 /IM)
or tunicamycin (0.5 /ig/ml) for 20 h to inhibit N-glycosylation. All
inhibitors were purchased from Boehringer Mannheim GmbH.
CDa-\r-T cells
CD4 + ~T ceils
allogeTieic PBL
Jurkat cells
0 1 2 3 4 5 6 7 B
TNF [ng/ml]
Fig. I. TNF release of monocytes stimulated with normal and
neoplastic cells. Monocytes (10''/culture) were cultured with viable
Jurkat cells. CD8 '-T-cells (3025), CD4 + -T-cells (C3F8) and PBL
from a different donor (2 x 10^  each/culture) for 18 h at 37 C. TNF
concentrations in the supernatants were measured by ELISA. The
data were obtained from quadruplicate cultures and are expressed
as mean + SD.
Mannheim, Germany. After the culture period cell viability was
greater than 95% as tested by trypan blue exclusion.
SDS-PAGE and Western blot. Plasma membrane preparations of
Jurkat cells (2 x lO^lane) were electrophoresed on a 12% poiyacryl-
amide gei (PAGE) and transferred to NC by electroblotting (2 h. 150
mA) [17]. The NC-sheet was cut into appropriate pieces according to
the molecular weight markers, placed in wells of a 24-well culture
plate (Costar) and the pieces were dissolved with 0.5 ml methanol.
The methanol was evaporated overnight and PBL(5x 1 Orwell) were
seeded into the wells. Afler 18 h of incubation TNF in the supernatant
was measured by ELISA.
FACS analysis. Cells (lOVanalysis) were incubated with FITC-
coupled anti-CD2 Ab (Clon lOT-Il. Dianova GmbH. Hamburg,
Germany) for 30 min on ice. washed and analysed with a FACScan
(Becton-Dickinson, San Jose. CA. USA).
CD2-Depletion. The samples from the HPLC gel permeation run
were incubated with anti-CD2 MoAb (I /jg/ml; Clon 8E5. Dr. B.
Schraven. DKFZ. Heidelberg, Germany) for 30 min. Subsequently
Protein A conjugated to Sepharose (10 mg/ml, Pharmacia) was added
and after 30 min the sepharose beads were removed by centrifugation.
RESULTS
Stimulation of human monocytes for TNF production by
neoplastic but not by normal cells
It has been shown by several groups that tumour cells can
stimulate monocytes to secrete TNF into the culture super-
natant, whereas normal cells cannot. In our experimental
system we cultured human peripheral blood monocytes from
healthy donors with viable Jurkat cells. Cells from a CD8^-T-
cell clone (3025) and from a CD4 * -T-cell clone (C3F8), as well
as PBL derived from a different donor were used as control.
Only the Jurkat cells induced TNF-secretion from monocytes,
while the other cells did not induce TNF levels greater than
background (Fig. 1).
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Fig. 2. TNF release of monocytes stimulated with treated Jurkat
cells. Monocytes (lO^/culture) were incubated wilh UV-irradiated
Jurkal cells (2 x 10 /^cuUure) treated with sodium periodate or
glutaraldehyde. After 20 h the TNF concentrations in the
supernatants were measured by ELISA. The experiment was
performed as triplicate cultures and the data are expressed as
mean -l- SD.
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Fig. 3. TNF release of monocytes stimulated with size-fractionated
Jurkat cell membrane preparations. Plasma membranes from
Jurkat cells (5 x 10*) were prepared and subjected to HPLC gel-
filtration. The samples were dialysed and incubated with
monocytes (IO''/culture). After 20 h the TNF concentrations in the
supernatants were measured by ELISA. The cxperimenl was
performed in triplicate cultures and the data are expressed as
mean + SD.
Previous experiments [9] showed that Jurkat cells them-
selves neither express TNF mRNA nor TNF protein and,
therefore, cannot account for TNF production. Thus the
question arose of whether Jurkat cells release a TNF inducing
factor (TIF) or whether they express TIF on their plasma
membranes. In order to destroy the metabolic activity of the
tumour cells, Jurkat cells were killed by UV-irradiation.
Again, only tumour cells but not normal cells induced TNF
secretion (data not shown). This supported the idea that
monocytes recognize tumour cells by a constituent exposed on
the plasma membrane.
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Fig. 4. TNF release of monocytes stimulated with membrane
fractions from Jurkat cells cultured with glycosylation inhibitors.
Jurkat cells (3 x 10* each) were cultured with (•) swainsonine, (•)
DMM, (T) tunicamycin, (*) castanospermine or (O) without any
inhibitor. Plasma membranes were prepared. HPLC-sized and
incubated with monocytes (10''/cuiture). After IK h the TNF
concentrations in the supernatants were measured by ELISA. The
experiment was performed three times and the data shown are
from one representative experiment. The dashed line represents
samples ofa control run with ovalbumin (43 kDa) eluting in
fraction no. 12.
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Fig. 5. TNF release of monocytes stimulated with 2-CD2 MoAb
treated Jurkat cells. Monocytes (10''/culture) were incubated with
Jurkat cells (solid bars) or K.562 cells (hatched bars) (2 x 10^  each/
culture). Tumour cells were treated with mouse 0!-hCD2 MoAb
(8E5; lgG2a ) and monocytes were treated with mouse a-hLFA-3
MoAb (TS2/9; IgGl) for 30 min before stimulation. Each MoAb
was used at 10 /ig/ml. After 20 h the TNF concentrations in the
supernatants were measured by ELISA. The experiment was
performed as quadruplicate cultures and the data are expressed as
mean + SD. The dashed line represents TNF levels in isotype
control experiments.
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Fig. 6. TNF release of monocytes treated with CD2-depleted
Jurkat cell membrane fractions. Plasma membranes from Jurkat
cells (10') were prepared and size fractionated using HPLC. 1/3 of
the samples were (•) CD2-depleted (Q:-CD2 MoAb concentration 5
/jg/ml). Monocytes (lO^culture) were either pretreated with
(A) a-LFA-3 MoAb (5 ;ig/m!) or (O) no Ab. After 20 h the TNF
concentrations in the supernatants were measured by ELISA. The
experiment was performed twice. Results from duplicate cultures
are expressed as mean f SD. The dashed line represents the TNF
background released by unstimulated monocytes. Ovalbumin (43
kDa) eluted in fraction no. 12.
Table 1. PH-stability of TIF. Plasma membranes from Jurkat cells
(2 X 10'') were prepared, sized and the fractions were tested for
activity. The active fraction was aliquoted. dialysed for 12 h with
Isotonic buffers of dilTerent pH and redialysed for 4 h with RPMI
1640. The treated aliquots were then incubated with monocytes
(lO''/culture). After 18 h the TNF concentrations in the
supernatants were measured by ELISA. The experiment was
performed as triplicate cultures and the data are expressed as
mean + SD.
pH 2 3 4 5 6 7 8 9 10 II 12
TNF [ng/ml] 2.3 2.1 2.0 2.7 9.2 8.4 9.0 8.4 9.4 7.8 6.6
SD 0.2 0.1 0.2 0.2 0.5 0.2 0.4 0.1 0.3 0.4 0.1
Biochemical modification of the tumour cell surface
Fxperiments with protein or carbohydrate-modifying chemi-
cals were performed to answer the question of whether a
protein or a carbohydrate structure was responsible for
monocyte activation. For this reason, UV-irradiated Jurkat
cells were treated with either glutaraldehyde- or sodium
periodate solution. The results revealed that the monocyte-
stimulating properties were destroyed after periodate treat-
ment (40% of the untreated control), while the glutaraldehyde
treatment left the stimulating capacity of the tumour cells
Table 2. TNF release kinetics from monocytes. Plasma membranes
from Jurkat cells (lO*") were prepared, sized, and the fractions were
tested for activity. The active fraction was aliquoted and incubated
with monocytes (IO''/monocytes). In parallel monocytes were
incubated with LPS from S. minnesota at 5 fig/ml. After 1, 2, 3, 4,
6, 9, 19, 24 h supernatants were collected and frozen at —2O'-C.
The TNF concentrations in the supernatants were measured by
ELISA. The experiment was performed as triplicate cultures and
the data are expressed as mean + SD.
Incubation
period [h]
1
2
3
4
6
9
19
24
Membrane
preparation
0.9-1-0.1
0.9 + 0.2
0.9 + 0.1
0.9 ±0.2
0.9 + 0.3
2.7 + 0.4
7.3 + 0.3
7.5 ±1.0
TNF [ng/ml]
LPS
0.9 + 0.2
0.9 + 0.2
2.2 + 0.2
0.9 + 0.3
7.0 + 0.5
14.5 + 0.9
15.8+1.0
15.0±0.9
Unstimulated
monocytes
0.6 + 0.1
0.3+0.1
0.3 + 0.1
0.4 ±0.1
0.9 + 0.1
L9 + 0.1
2.6 + 0.2
2.2 ±0.2
nearly unaffected (77% of the untreated control; Fig. 2).
Figure 2 shows data of a representative experiment. The
remaining stimulatory activity of tumour cells in repeated
experiments varied from 10% to 40% after periodate treat-
ment and from 77% to 90% after glutaraidehyde treatment. In
experiments where Jurkat cell membrane constituents had
been separated by PAGE the active fraction recovered from
the gel lost its monocyte-activating capacity completely after
periodate treatment (data not shown). This was the first
indication of carbohydrates playing a role in tumour-speciiic
monocyte stimulation. Similar results were obtained at the
mRNA level. After glutaraldehyde treatment Jurkat cells as
well as K562 cells were capable of inducing TNF mRNA
production whereas periodate treatment of the tumour cells
destroyed this activity (data not shown).
Separation of tumour cell membranes bv HPLC gel-filtration
In prelimininary experiments Jurkat cell membranes were
separated by SDS-PAGE, blotted onto Nitrocellulose, and
thereafter applied to monocyte cultures by dissolving the
nitrocellulose pieces in methanol. It could be demonstrated
that membrane constituents of the molecular size in the range
of 37-47 kDa stimulated monocytes for TNF production and
release. To confirm this and in order to gather further
information on thc biochemical and physical structure of TIF
Jurkat cell membranes were size-chromatographed by HPLC
gel-filtration to obtain TIF in larger quantities. The fractions
were tested for their monocyte-stimulating capability after
eiution from the sizing column and dialysis. Fraction number
12 (corresponding to the apparent molecular weight of 43
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kDa) activated monocytes for TNF secretion (Fig. 3). The
fractions that contained TIF were used for pH-stability tests
and TNF release kinetics. Plasma membranes from K562 cells
were equally sized-separated on HPLC and tested for mono-
cyte stimulation. The membranes prepared from K562 cells
also displayed TIF at a molecular size of about 45 kDa (data
not shown).
pH-stability and TNF release kinetics of TIF
Sized plasma membrane fractions from Jurkat cells were
tested for TNF-inducing capacity and subsequently used for
TNF release kinetics or for testing the pH-stability. To check
the resistance of TIF to pH-changes the TIF bearing fraction
was dialysed against buffers covering pH-values from 2 to 12
for 12 h and redialysed into RPMI 1640 for 8 h. Table I shows
TNF secretion by human monocytes after incubation with
such treated fractions. TIF was stable in a range from pH 6 to
10. Incubation of monocytes with TIF for various periods of
time showed that TIF induced TNF levels greater than
background after 9 h of incubation (LPS., in comparison,
induced TNF secretion after 6 h of incubation) and reached a
plateau after 19 h (LPS 9 h) (Table 2).
Effeet of glycosylation inhibitors
Jurkat cells were cultured in the presence of glycosylation
inhibitors to investigate the role of carbohydrates in the
tumour-specific stimulation process. Swainsonine, 1-deoxy-
mannojirimycin, castanospermine or tunicamycin were used.
These substances block the addition and trimming of sugar
structures at different stages during the N-glycosylation
process of mammalian cells. After a 20 h culture period the
Jurkat cells were harvested, plasma membranes were pre-
pared, sized on HPLC, and incubated with monocytes for
20 h. The TNF concentrations in the supernatants are shown
in Fig. 4. Plasma membranes derived from Jurkat cells
cultured with non-supplemented medium stimulated mono-
cytes for TNF release. In contrast, none of the 43 kDa
fractions of the membrane preparations with a glycosylation
pattern absent, incomplete or changed due to the inhibitors
were able to induce TNF secretion.
For control purposes the presence of typical membrane
structures on the cell surface was tested in parallel. Flow
eytometrical analysis revealed that Jurkat eells were positive
for the CD2 molecule whether or not they had been cultured
with a glycosyiation inhibitor. This indicated the correct
transport of glycosylated membrane molecules to the cell
surface even when glyeosylation was disturbed.
Effects ofanti-CD2 (oc-CD2 MoAb) and anti-LF A-3
antibodies fci-LFA-3 MoAb) on the stimulating potency of
Jurkat cells
Deduced from the results shown above and in view of recently
published data [18] the role of CD2 in the monocyte activation
process was investigated. For this reason UV-irradiated
Jurkat cells were incubated with a-CD2 MoAb and then
incubated with monocytes. In addition, the ligand of CD2, the
lymphocyte function-associated antigen-3 (LFA-3) on the
surface of monocytes was blocked with a-LFA-3 MoAb. TNF
secreted by the monocytes was measured after a 20 h culture
period. UV-irradiated K562 cells were used as CD2-negative
control. As can be seen from Fig. 5, both MoAbs blocked the
stimulation of monocytes. The capacity of the K562 cells for
TNF induction was not affected by the presence of the MoAb.
This led to the conclusion that CD2 was involved in the
stimulation of monocytes by Jurkat cells. It also demonstrated
that monocyte stimulation by K562 cells was different from
the CD2-LFA-3 mechanism. Similar results were obtained
when plasma membrane preparations were used instead of
complete Jurkat cells (Fig. 6). Size-fractionated membranes
from Jurkat cells were CD2-dep]eted by immunoprecipitation
and used for stimulation. Also, non CD2-depleted active
Jurkat cell membrane fractions were used to stimulate mono-
cytes bearing MoAb-blocked LFA-3. Again, untreated mem-
brane preparations of about 43 kDa stimulated monocytes to
secrete TNF. However, CD2-depletion of membrane or anti-
LFA-3 treatment of the monocytes abolished TNF release.
DISCUSSION
Despite the fact that specific recognition of tumour cells by
monocytes has been described in many systems, it is still
unclear how monocytes/macrophages distinguish betweeti
normal and neoplastic cells. Results from Fidler [10], Shimizu
[11], Hasday [12], Janicke & Mannel [9], and Chong et al. [19]
showed that monocytes specifically bind and destroy tumour
cells of syn-, allo-, and xenogeneic origin. We support this
observation in our system demonstrating that only tumour
cells, not allogeneic PBL or non-neoplastic T-cell lines, caused
TNF secretion by monocytes. Janicke & Mannel [9] and
Chong et al. [19] also showed that the activating principle was
located on the tumour cell surface. To date little is known
about the molecular mechanism of action and the biochemical
nature of this TNF-inducing factor. Chong et al. found that
the TNF-inducing capacity of tumour cells was lost after
periodate treatment. Fidler and coworkers discussed an
altered lipid-composition on tumour cells as cause for the
selective recognition process [20]. This hypothesis is not
supported by the data of Hasday et al. who recovered TNF-
inducing membrane molecules from murine tumours in the
aqueous phase after methanol:water:chloroform extraction
[12]. The sensitivity to periodate as well as the solubility in
water (HPLC runs were performed without detergents) was
also shown in our experiments. The importance of carbo-
hydrate structures for the activation process was stressed by
the use of glycosylation inhibitors. The glycosylation inhibi-
tors used in our experiments affect the glycosylation of
proteins at different stages: Tunicamycin inhibits N-glycosyla-
tion completely by inhibiting the enzyme glycosyltransferase.
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Castanospermin inhibits glucosidase I resulting in modified
complex or hybrid carbohydrate structures. DMM is a
mannose analogon leading to high-mannose structures.
Swainsonine inhibits the building of complex structures by
trimming the glycoproteins but does not aff"ect the develop-
ment of high-mannose or hybrid structures. After treatment
with each ofthese glyeosylation inhibitors all TIF activity had
disappeared in the molecular weight range of 43 kDa. The
reason for the appearance ofa TNF-inducing fraction in the
molecular weight range of 35 kDa (Fig. 4, fraction No. 14)
after castanospermin incubation of the Jurkat cells is unclear
but could be due to synthesis of biologically active partial
structures of TIF. However, the appearance of this peak of
activity was not reproducible in repeated experiments. The
presence of CD2 was measured by immunofluorescence to rule
out the possibility that the stimulation of the monocytes was
lost after inhibition of glycosylation because the non-glycosy-
lated proteins might not be transported to and expressed on
the cell surface. The CD2 molecule was still detectable at
comparable intensities on more than 94% of the cells whether
cultured in the presence or absence of inhibitors.
Furthermore, Jurkat cells were cultured without FCS to
minimize the possibility that serum components were respon-
sible for the TNF release. The plasma membrane preparations
from such cells activated monocytes as well as preparations
from Jurkat cells cultured with FCS (data not shown). This
indicated that TIF is an intrinsic factor of the tumour cells.
Contaminating bacterial endotoxin, mycoplasma or viral
components could not account for the observed monocyte
activation for several reasons: Both tumour cell lines (Jurkat
and K562) were tested regularly for the absence of viral
structures and mycoplasma. Endotoxin contamination was
excluded since control cells were cultured and subjected to
identical fractionating procedures as the tumour cells and did
not activate the monocytes. Furthermore, the difference in
kinetics for TIF-induced versus LPS-induced TNF release
also indicated different signalling pathways for the two
stimuli.
Recently Webb et al. described TNF stimulating capability
of CD2 isolated from Jurkat cells [18] and magrophage-
colony-stimulating factor production subsequent to LFA-3
triggering[21]. However, thequestion remains whether Jurkat
ceII-CD2 is identical with T-cell CD2 or whether it is
glycosylated in a different way. Reinherz et al. demonstrated
the importance of glycosylation of the CD2 molecule for the
functional three-dimensional structure of the protein part [22].
Also, the quantity of CD2 expressed by some tumour cells
could differ from the quantity on normal T-cells and the
stimulating phenomenon could be a matter of CD2-concen-
trations on the tumour cell surface seen by the monocytes.
Investigations to answer these questions are in progress.
lt is of interest that the CD2-negative K.562 tumour cells
also exposed carbohydrate structures on the membrane that
activated monocytes. This structure was also inactivated by
periodate treatment but not affected by glutaraldehyde (data
not shown). Therefore, a carbohydrate conformation com-
mon to tumour cells might be responsible for activation of
mononuclear phagocytes rather than a protein tumour
marker. Quantitative isolation, purification and comparative
biochemical analysis of the monocyte-activating carbo-
hydrate structures from different tumour cells will be required
to solve this problem.
In summary, the characteristics of the monocyte activating
structures determined in our system are: (1) they are plasma
membrane constituents and exposed to the outside; (2) in thc
case of K562 and Jurkat cells the molecular weight is about
45,000 Da; (3) the biologically active part ofthese structures
resides most likely in carbohydrate moieties; and (4) in the case
of Jurkat cells the activating structure seetns to be part of the
CD2-molecule.
The possibility of finding common features of the mono-
cyte-activating principle from different tumour cells and
pinpointing those to molecularly defined structures is in-
triguing and worthy of further investigation with the aim of
gaining a better understanding of tumour cell-monocyte
communication with possible consequences for future diag-
nostic and therapeutic purposes.
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